Evidence map›Paper›PMID 39494457›Full record

ArticleOpen forum infectious diseases2024

Altered Spike Immunoglobulin G Fc N-Linked Glycans Are Associated With Hyperinflammatory State in Adult Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome in Children.

Jacob D Sherman, Vinit Karmali, Bhoj Kumar, Trevor W Simon, Sarah Bechnak, Anusha Panjwani, Caroline R Ciric, Dongli Wang, Christopher Huerta, Brandi Johnson and 6 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Jacob D ShermanDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0009-0002-2597-7654
Vinit KarmaliDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Bhoj KumarComplex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.ORCID https://orcid.org/0000-0001-8311-7025
Trevor W SimonDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-9930-1011
Sarah BechnakDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Anusha PanjwaniDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Caroline R CiricDivision of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Dongli WangDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Christopher HuertaDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Brandi JohnsonDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Evan J AndersonDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Nadine RouphaelDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-2512-7919
Matthew H CollinsDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-7974-1933
Christina A RostadDivision of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8439-0592
Parastoo AzadiComplex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.ORCID https://orcid.org/0000-0002-6166-9432
Erin M SchererDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-8794-1932

Funding

Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG) - Momi-Vax DMID #21-0004 {Supplement #6}UM1AI148684 · NIAID · EMORY UNIVERSITY · PI DAVID S STEPHENS · 2020 to 2026
$77.2M
VTEU SupplementUM1AI148689 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Karen L. Kotloff · 2020 to 2026
$52.7M
Vanderbilt Vaccine and Treatment Evaluation Unit - KidCOVEUM1AI148452 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Clarence Buddy Creech · 2020 to 2026
$51.3M
Vaccine and Treatment Evaluation Units - DMID 21-0012UM1AI148576 · NIAID · EMORY UNIVERSITY · PI Nadine Georges Rouphael, Carlos del Rio · 2020 to 2026
$41.7M
Vaccine and Treatment Evaluation Unit at Saint Louis University - DMID 20-0034UM1AI148685 · NIAID · SAINT LOUIS UNIVERSITY · PI Daniel F. Hoft · 2020 to 2026
$34.6M
Vaccine and Treatment Evaluation Units (VTEU)-DMID 21-0004UM1AI148575 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HANA M EL SAHLY · 2020 to 2026
$29.4M
University of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012UM1AI148573 · NIAID · UNIVERSITY OF WASHINGTON · PI Raymond Scott McClelland, Anna Wald · 2020 to 2026
$26.6M
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)-mRNA-1273-P204 Moderna Pediatric StudyUM1AI148450 · NIAID · UNIVERSITY OF ROCHESTER · PI Angela Ramona Branche, Ann R Falsey · 2020 to 2026
$20.6M
National Glycoscience Resource- CCRC Service and Training - NGlycoR@CCRCR24GM137782 · NIGMS · UNIVERSITY OF GEORGIA · PI Parastoo Azadi · 2020 to 2026
$5.2M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS UM1 AI148450NIAID NIH HHS UM1 AI148452NIAID NIH HHS UM1 AI148573NIAID NIH HHS UM1 AI148575NIAID NIH HHS UM1 AI148576NIAID NIH HHS UM1 AI148684NIAID NIH HHS UM1 AI148685NIAID NIH HHS UM1 AI148689NIGMS NIH HHS R24 GM137782
6 · The paper itself

Abstract

Background: Severe coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome (MIS-C) are characterized by excessive inflammatory cytokines/chemokines. In adults, disease severity is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific immunoglobulin G (IgG) Fc afucosylation, which induces proinflammatory cytokine secretion from innate immune cells. This study aimed to define spike IgG Fc glycosylation following SARS-CoV-2 infection in adults and children and following SARS-CoV-2 vaccination in adults and the relationships between glycan modifications and cytokines/chemokines. Methods: We analyzed longitudinal (n = 146) and cross-sectional (n = 49) serum/plasma samples from adult and pediatric COVID-19 patients, MIS-C patients, adult vaccinees, and adult and pediatric controls. We developed methods for characterizing bulk and spike IgG Fc glycosylation by capillary electrophoresis and measured levels of 10 inflammatory cytokines/chemokines by multiplexed enzyme-linked immunosorbent assay. Results: Spike IgG was more afucosylated than bulk IgG during acute adult COVID-19 and MIS-C. We observed an opposite trend following vaccination, but it was not significant. Spike IgG was more galactosylated and sialylated and less bisected than bulk IgG during adult COVID-19, with similar trends observed during pediatric COVID-19/MIS-C and following SARS-CoV-2 vaccination. Spike IgG glycosylation changed with time following adult COVID-19 or vaccination. Afucosylated spike IgG exhibited inverse and positive correlations with inflammatory markers in MIS-C and following vaccination, respectively; galactosylated and sialylated spike IgG inversely correlated with proinflammatory cytokines in adult COVID-19 and MIS-C; and bisected spike IgG positively correlated with inflammatory cytokines/chemokines in multiple groups. Conclusions: We identified previously undescribed relationships between spike IgG glycan modifications and inflammatory cytokines/chemokines that expand our understanding of IgG glycosylation changes that may impact COVID-19 and MIS-C immunopathology.

Indexed as

antibody glycosylationCOVID-19FcinflammationMIS-C

Identifiers

PMID39494457
PMCPMC11528514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.